• LAST PRICE
    4.0500
  • TODAY'S CHANGE (%)
    Trending Up0.0500 (1.2500%)
  • Bid / Lots
    4.0000/ 9
  • Ask / Lots
    4.0900/ 2
  • Open / Previous Close
    4.1200 / 4.0000
  • Day Range
    Low 4.0000
    High 4.1200
  • 52 Week Range
    Low 2.8888
    High 6.7499
  • Volume
    4,382
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Wednesday's close: 4
TimeVolumeNRBO
09:36 ET5004.12
09:50 ET9004.12
09:52 ET1004.1199
09:54 ET1814
10:37 ET1404.08
11:06 ET2004.045
11:09 ET5504.045
11:33 ET1504
01:15 ET7004.05
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesNRBO
NeuroBo Pharmaceuticals Inc
19.6M
-1.2x
---
United StatesPPBT
Purple Biotech Ltd
19.7M
-1.1x
---
United StatesVINC
Vincerx Pharma Inc
19.5M
-0.4x
---
United StatesNRSN
Neurosense Therapeutics Ltd
20.0M
-1.5x
---
United StatesAPTO
Aptose Biosciences Inc
18.6M
-0.2x
---
United StatesEVAX
Evaxion Biotech A/S
18.7M
-0.1x
---
As of 2024-05-30

Company Information

NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and T2DM. Agonism of GPR119 in the gut promotes the release of key gut peptides, glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide, and peptide YY. DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is to be administered once weekly subcutaneously. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure.

Contact Information

Headquarters
545 Concord Avenue, Suite 210CAMBRIDGE, MA, United States 02138
Phone
857-702-9600
Fax
734-293-0444

Executives

Independent Chairman of the Board
Andrew Koven
President, Chief Executive Officer, Director
Hyung Kim
Chief Financial Officer
Marshall Woodworth
Independent Director
Mark Glickman
Independent Director
Jason Groves

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$19.6M
Revenue (TTM)
$0.00
Shares Outstanding
4.9M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
-0.28
EPS
$-3.26
Book Value
$3.40
P/E Ratio
-1.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.